Expiration date: 01/2026

The active substance:

blueberry ordinary fruit (Bilberry fruit)

ATX Code

S01XA (Other drugs for the treatment of eye diseases)

Release form, packaging and composition of the drug

The capsules are soft gelatinous, oval, dark brown in color with a slightly shiny smooth surface.

1 capsule contains:

dry extract of blueberry fruit 177 mg

[PRING] soybean oil, hydrogenated vegetable fats, gelatin, glycerol, red iron oxide, black iron oxide, sodium ethylparahydroxybenzoate, sodium propylparahydroxybenzoate.

20 pcs. - blisters (1) - cardboard packs.

Clinical and Pharmacological group

A drug that improves the functional state of the retina for systemic use in ophthalmology

Pharmaco-therapeutic group

Plant-based remedy

Indications for use

• myopia of medium and high degree;
• acquired hemeralopia;
• diabetic retinopathy;
• violation of the mechanisms of adaptation of vision to darkness (with night and twilight vision);
• muscular asthenopia;
• central atherosclerotic retinal degeneration of the Kuntunius type;
• tapetoretinal retinal abiotrophy (retinal pigment degeneration).

Dosage

The drug is prescribed orally 1 capsule 3 times / day. The course of treatment is 1 month.

Contraindications

individual hypersensitivity to the active substance of the drug or to any auxiliary ingredients included in its composition.

Overdose

To date, no cases of overdose of the drug Myrtilene forte have been reported.

Side effects

Possible: allergic reactions.

Overdose

The drug interaction of the drug Myrtilene forte is not described.

Storage conditions

List B. The drug should be stored out of the reach of children at a temperature no higher than 25 ° C.

Special instructions

Currently, there are no reliable data on the use of the drug Myrtilene forte in children. Therefore, the drug should be used in this category of patients only if the expected benefit exceeds the potential risk.